vs

Side-by-side financial comparison of AMERISAFE INC (AMSF) and Axogen, Inc. (AXGN). Click either name above to swap in a different company.

AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $61.5M, roughly 1.3× Axogen, Inc.). AMERISAFE INC runs the higher net margin — 10.2% vs -31.9%, a 42.0% gap on every dollar of revenue. On growth, Axogen, Inc. posted the faster year-over-year revenue change (26.6% vs 10.3%). Over the past eight quarters, Axogen, Inc.'s revenue compounded faster (13.3% CAGR vs 2.8%).

AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.

Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering (IPO). Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is...

AMSF vs AXGN — Head-to-Head

Bigger by revenue
AMSF
AMSF
1.3× larger
AMSF
$80.1M
$61.5M
AXGN
Growing faster (revenue YoY)
AXGN
AXGN
+16.2% gap
AXGN
26.6%
10.3%
AMSF
Higher net margin
AMSF
AMSF
42.0% more per $
AMSF
10.2%
-31.9%
AXGN
Faster 2-yr revenue CAGR
AXGN
AXGN
Annualised
AXGN
13.3%
2.8%
AMSF

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMSF
AMSF
AXGN
AXGN
Revenue
$80.1M
$61.5M
Net Profit
$8.1M
$-19.6M
Gross Margin
75.2%
Operating Margin
20.2%
Net Margin
10.2%
-31.9%
Revenue YoY
10.3%
26.6%
Net Profit YoY
-9.0%
-410.8%
EPS (diluted)
$0.43
$-0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMSF
AMSF
AXGN
AXGN
Q1 26
$80.1M
$61.5M
Q4 25
$81.6M
$59.9M
Q3 25
$82.0M
$60.1M
Q2 25
$81.1M
$56.7M
Q1 25
$72.6M
$48.6M
Q4 24
$74.0M
$49.4M
Q3 24
$78.7M
$48.6M
Q2 24
$75.8M
$47.9M
Net Profit
AMSF
AMSF
AXGN
AXGN
Q1 26
$8.1M
$-19.6M
Q4 25
$10.4M
$-13.2M
Q3 25
$13.8M
$708.0K
Q2 25
$14.0M
$579.0K
Q1 25
$8.9M
$-3.8M
Q4 24
$13.2M
$450.0K
Q3 24
$14.3M
$-1.9M
Q2 24
$11.0M
$-1.9M
Gross Margin
AMSF
AMSF
AXGN
AXGN
Q1 26
75.2%
Q4 25
74.1%
Q3 25
76.6%
Q2 25
74.2%
Q1 25
71.9%
Q4 24
76.1%
Q3 24
74.9%
Q2 24
73.8%
Operating Margin
AMSF
AMSF
AXGN
AXGN
Q1 26
20.2%
Q4 25
15.6%
-16.3%
Q3 25
21.3%
3.2%
Q2 25
21.5%
3.0%
Q1 25
15.5%
-3.4%
Q4 24
22.7%
4.1%
Q3 24
22.6%
-0.6%
Q2 24
18.1%
-0.9%
Net Margin
AMSF
AMSF
AXGN
AXGN
Q1 26
10.2%
-31.9%
Q4 25
12.8%
-22.0%
Q3 25
16.9%
1.2%
Q2 25
17.2%
1.0%
Q1 25
12.3%
-7.9%
Q4 24
17.8%
0.9%
Q3 24
18.2%
-3.8%
Q2 24
14.5%
-4.0%
EPS (diluted)
AMSF
AMSF
AXGN
AXGN
Q1 26
$0.43
$-0.38
Q4 25
$0.55
$-0.28
Q3 25
$0.72
$0.01
Q2 25
$0.73
$0.01
Q1 25
$0.47
$-0.08
Q4 24
$0.69
$-0.00
Q3 24
$0.75
$-0.04
Q2 24
$0.57
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMSF
AMSF
AXGN
AXGN
Cash + ST InvestmentsLiquidity on hand
$34.2M
$82.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$246.6M
$244.8M
Total Assets
$289.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMSF
AMSF
AXGN
AXGN
Q1 26
$34.2M
$82.7M
Q4 25
$61.9M
$41.5M
Q3 25
$54.7M
$35.8M
Q2 25
$48.5M
$29.9M
Q1 25
$44.8M
$22.1M
Q4 24
$44.1M
$33.5M
Q3 24
$63.7M
$24.5M
Q2 24
$30.6M
$21.1M
Total Debt
AMSF
AMSF
AXGN
AXGN
Q1 26
Q4 25
$48.4M
Q3 25
$48.2M
Q2 25
$47.9M
Q1 25
$47.7M
Q4 24
$47.5M
Q3 24
$47.3M
Q2 24
$47.0M
Stockholders' Equity
AMSF
AMSF
AXGN
AXGN
Q1 26
$246.6M
$244.8M
Q4 25
$251.6M
$128.8M
Q3 25
$274.8M
$120.8M
Q2 25
$265.6M
$112.3M
Q1 25
$260.8M
$105.4M
Q4 24
$257.3M
$103.9M
Q3 24
$314.4M
$99.4M
Q2 24
$301.0M
$95.7M
Total Assets
AMSF
AMSF
AXGN
AXGN
Q1 26
$289.5M
Q4 25
$1.1B
$221.7M
Q3 25
$1.2B
$216.4M
Q2 25
$1.2B
$205.5M
Q1 25
$1.2B
$196.2M
Q4 24
$1.2B
$203.7M
Q3 24
$1.3B
$192.0M
Q2 24
$1.2B
$188.9M
Debt / Equity
AMSF
AMSF
AXGN
AXGN
Q1 26
Q4 25
0.38×
Q3 25
0.40×
Q2 25
0.43×
Q1 25
0.45×
Q4 24
0.46×
Q3 24
0.48×
Q2 24
0.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMSF
AMSF
AXGN
AXGN
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-1.4M
FCF MarginFCF / Revenue
-2.3%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMSF
AMSF
AXGN
AXGN
Q1 26
Q4 25
$11.1M
$3.0M
Q3 25
$10.7M
$3.2M
Q2 25
$-8.4M
$7.7M
Q1 25
$-1.8M
$-13.2M
Q4 24
$24.2M
$8.7M
Q3 24
$8.4M
$3.9M
Q2 24
$-2.6M
$4.2M
Free Cash Flow
AMSF
AMSF
AXGN
AXGN
Q1 26
$-1.4M
Q4 25
$8.9M
$1.8M
Q3 25
$9.8M
$1.7M
Q2 25
$-9.5M
$7.0M
Q1 25
$-1.8M
$-13.4M
Q4 24
$23.4M
$8.1M
Q3 24
$8.4M
$3.3M
Q2 24
$-2.6M
$3.3M
FCF Margin
AMSF
AMSF
AXGN
AXGN
Q1 26
-2.3%
Q4 25
10.9%
3.0%
Q3 25
11.9%
2.8%
Q2 25
-11.7%
12.4%
Q1 25
-2.5%
-27.7%
Q4 24
31.5%
16.3%
Q3 24
10.7%
6.8%
Q2 24
-3.5%
6.8%
Capex Intensity
AMSF
AMSF
AXGN
AXGN
Q1 26
Q4 25
2.6%
2.1%
Q3 25
1.1%
2.5%
Q2 25
1.3%
1.3%
Q1 25
0.0%
0.5%
Q4 24
1.1%
1.4%
Q3 24
0.0%
1.2%
Q2 24
0.1%
1.9%
Cash Conversion
AMSF
AMSF
AXGN
AXGN
Q1 26
Q4 25
1.06×
Q3 25
0.77×
4.55×
Q2 25
-0.61×
13.35×
Q1 25
-0.20×
Q4 24
1.83×
19.41×
Q3 24
0.59×
Q2 24
-0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons